Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Pfisterer J, Arnold N, Burchardi N, Schmalfeldt B, Huober J, Harter P, Kommoss F, Bentz E, du Bois A, Hilpert F. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009; 19:109-15.
01.01.2009
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
01.01.2009
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009; 19:109-15
Pfisterer Jacobus, Arnold Norbert, Burchardi Nicole, Schmalfeldt Barbara, Huober Jens, Harter Philipp, Kommoss Friedrich, Bentz Eva-Katrin, du Bois Andreas, Hilpert Felix
Weiter